WEBULL
News
ELTX
8.07
+2.67%
0.21
Weekly Report: what happened at ELTX last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at ELTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:56
Weekly Report: what happened at ELTX last week (1215-1219)?
Weekly Report · 12/22/2025 09:56
Elicio Therapeutics reports inducement grants
TipRanks · 12/16/2025 13:15
Elicio Therapeutics Grants Stock Options to New Employees
Reuters · 12/16/2025 13:00
Weekly Report: what happened at ELTX last week (1208-1212)?
Weekly Report · 12/15/2025 10:02
Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial
TipRanks · 12/11/2025 13:16
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Regeneron (REGN) and Elicio Therapeutics (ELTX)
TipRanks · 12/11/2025 13:10
Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy
Benzinga · 12/11/2025 13:04
Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS
Reuters · 12/11/2025 13:00
ELICIO THERAPEUTICS REPORTS ANTIGEN SPREADING TO PATIENT-SPECIFIC NEOANTIGENS BEYOND MKRAS IN ONGOING PHASE 2 AMPLIFY-7P TRIAL
Reuters · 12/11/2025 13:00
Weekly Report: what happened at ELTX last week (1201-1205)?
Weekly Report · 12/08/2025 10:00
Weekly Report: what happened at ELTX last week (1124-1128)?
Weekly Report · 12/01/2025 09:57
Weekly Report: what happened at ELTX last week (1117-1121)?
Weekly Report · 11/24/2025 10:01
Elicio Therapeutics appoints Marc Wolfgang as CTO
TipRanks · 11/19/2025 13:10
Elicio Therapeutics Names Marc J. Wolfgang as Chief Technology Officer
Reuters · 11/19/2025 13:00
Press Release: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Dow Jones · 11/19/2025 13:00
H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)
TipRanks · 11/19/2025 11:37
Weekly Report: what happened at ELTX last week (1110-1114)?
Weekly Report · 11/17/2025 10:01
JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)
TipRanks · 11/14/2025 13:16
More
Webull provides a variety of real-time ELTX stock news. You can receive the latest news about Elicio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.